{"id":"NCT03623321","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease","officialTitle":"A 52-Week Open-label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-17","primaryCompletion":"2023-05-05","completion":"2023-05-05","firstPosted":"2018-08-09","resultsPosted":"2024-12-20","lastUpdate":"2024-12-20"},"enrollment":595,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuropsychiatric Symptoms Related to Neurodegenerative Disease"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":[]}],"arms":[{"label":"Drug - pimavanserin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.","primaryOutcome":{"measure":"Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Treatment period and Follow-up period: 56 weeks","effectByArm":[{"arm":"Pimavanserin","deltaMin":238,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Bulgaria","Colombia","Czechia","Georgia","Mexico","Poland","Romania","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":595},"commonTop":[]}}